Testing an AI model that predicts when prostate cancer stops responding to hormone therapy
Tests an AI model predicting time to castration resistance in prostate cancer.
Plain-language title generated from the registry record
Registry title: Development and Prospective Validation of a Pathology-Based Artificial Intelligence Model for Predicting the Time to Castration Resistance of Prostate Cancer
Key facts
- Where
- Guangzhou, ChinaSee the site
Where in China
- Sun Yat Sen Memorial Hospital of Sun Yat sen UniversityGuangzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Trial code
- NCT07376057
- Record updated
- 29 January 2026
- Original description
The goal of this predictive test is to prospectively test the performance of pre-developed artificial intelligence (AI) predictive model for predicting the time to castration resistance of prostate cancer. Investigators had developed this AI model based on deep learning algorithms in preliminary research, and it performed well in retrospective tests.Read full original descriptionShow less
Development and Prospective Validation of a Pathology-Based Artificial Intelligence Model for Predicting the Time to Castration Resistance of Prostate Cancer
The goal of this predictive test is to prospectively test the performance of pre-developed artificial intelligence (AI) predictive model for predicting the time to castration resistance of prostate cancer. Investigators had developed this AI model based on deep learning algorithms in preliminary research, and it performed well in retrospective tests.
Inclusion: Patients are diagnosed with intermediate- to high-risk prostate cancer; undergo prostate biopsy; Patients only received endocrine therapy for prostate cancer; Patients with complete clinical and pathological information; Patients agree to participate in this diagnostic test.
Exclusion: Patients with other tumors and undergo systemic therapy ; The patient refused to participate in this diagnostic test.